- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01579526
A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers
May 16, 2012 updated by: Avalo Therapeutics, Inc.
A Randomized, Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers
The purpose of this study is to determine the safety and pharmacokinetics of FP01 in healthy volunteers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
INCLUSION CRITERIA
- Subjects are male and female volunteers 18 to 55 years of age inclusive.
- BMI between 18 and 30, inclusive.
- Subjects must have an estimated creatinine clearance rate of ≥ 80 mL/min as determined by the Cockcroft-Gault equation (see section 7.1).
- Female subjects of childbearing potential must be using adequate birth control as determined by the Investigator.
- Female subjects of childbearing potential must have negative pregnancy test results at screening and Day -1.
- Subjects must be able to provide informed consent after risks and benefits have been explained.
- Subjects must be non-smoking and non-tobacco user (defined as a subject who has not smoked or used tobacco products for ≥ 12 months from study screening), and must agree to abstain from alcohol and caffeine for 72 hours prior to study dosing and during their participation in the study.
- Subjects must have a 12 lead ECG without any clinically significant abnormalities of rate, rhythm, intervals or conduction, as determined by the Investigator.
- Subjects are in generally good health, based on pre-study medical history, physical examination and routine laboratory tests, as determined by the Investigator.
- Subjects who have no clinically significant disease and/or clinically significant abnormal laboratory values as determined by the Investigator based on medical history, physical examination, or laboratory evaluations conducted at the screening visit or on admission to the clinic.
- Be willing and able to comply with the study protocol requirements for the duration of the study, including pharmacokinetic sampling
EXCLUSION CRITERIA
- Females who are pregnant or lactating.
- Subjects who have a history of drug or alcohol abuse within 12 months of study screening, as determined by the Investigator.
- Subjects who have participated in any investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the start of the study (time of first dose).
- Subjects who have clinically significant medical or psychiatric illnesses currently or within 30 days of start of study (time of first dose), as determined by the Investigator.
- Subjects with any oral lesions observed at screening visit or at the Day -1 visit.
- Subjects who have a history of significant allergies (including history of asthma, food, or drug allergies), as determined by the Investigator.
- Subjects who have had significant blood loss, or have donated or received one or more pints of blood within 30 days prior to dosing.
- Subjects who have had symptoms of any significant acute illness including upper respiratory infections within 30 days prior to the start of study (time of first dose), as determined by the Investigator.
- Subjects who have any condition that interferes with their ability to understand or comply with the requirements of the study.
- Subjects who have a positive drug screen or alcohol screen at study screening or Day -1.
- Subjects who have any disease or condition (medical or surgical) that might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or central nervous system function; or any other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the study drug, or that would place the subject at increased risk, as determined by the Investigator.
- Subjects who have a positive result at screening for HIV, Hepatitis B, or Hepatitis C.
- Subjects who have received any concomitant prescription, over-the-counter, or herbal medications 7 days prior to study dosing, with the exception of hormonal contraceptives and up to 3 doses of acetaminophen at a dose of 1 gram or less from the time of study screening to the time of study dosing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FP01 Dose 1
Drug
|
comparison of different dosages
|
Experimental: FP01 Dose 2
Drug
|
comparison of different dosages
|
Experimental: FP01 Dose 3
Drug
|
comparison of different dosages
|
Active Comparator: Comparator
Drug
|
comparison of different dosages
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma pharmacokinetic profiles of the active pharmaceutical ingredient
Time Frame: various timepoints over 72 hours
|
Plasma PK profiles: various PK indices including, but not limited to, peak plasma concentration (Cmax), Area under the plasma concentration versus time curve (AUC), and elimination half-life (T1/2), and time to peak plasma concentration (Tmax).
|
various timepoints over 72 hours
|
Safety and Tolerability
Time Frame: Various Timepoints over 72 Hours
|
Safety and Tolerability will take into account the recorded AEs, vital signs, and clinical and laboratory assessments.
|
Various Timepoints over 72 Hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
April 1, 2012
Study Completion (Actual)
May 1, 2012
Study Registration Dates
First Submitted
April 6, 2012
First Submitted That Met QC Criteria
April 17, 2012
First Posted (Estimate)
April 18, 2012
Study Record Updates
Last Update Posted (Estimate)
May 17, 2012
Last Update Submitted That Met QC Criteria
May 16, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Other Study ID Numbers
- Clin01-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on FP01
-
Avalo Therapeutics, Inc.CompletedChronic Refractory CoughUnited States
-
Avalo Therapeutics, Inc.Completed